Bari International Conference

Home > Programme

Programme

Download entire programme in .pdf herebelow

Saturday, 17 May 2008

Registration

Sunday, 18 May 2008

Scientific Session 1
Chairs: PM Mannucci (Italy), N Ciavarella (Italy)
J Ingerslev (Denmark) Investigating the dynamic properties of hemostasis
J Eikenboom (The Netherlands) Determinant of plasma levels of factor VIII and von Willebrand factor
K Mertens (The Netherlands) Cellular mechanisms in the secretion and endocytosis of the factor VIII-von Willebrand factor complex
R Camire (USA) Novel factor Xa variants For improving hemostasis in hemophilia

Chaird: D Lillicrap (Canada), R Montgomery (USA)
T van den Driessche (Belgium) Gene therapy for hemophilia: efficacy, safety and immune consequences
L Naldini (Italy) A microRNA-regulated lentiviral vector mediates stable correction of hemophilia B mice
D Lillicrap (Canada) Ex vivo gene transfer for hemophilia A using genetically-modified adult endothelial progenitor cells
R Montgomery (USA) Factor VIII and beyond - the platelet for target drug delivery

Satellite Symposia

Wyeth (Videoproceedings available on DVD - contact hemocongress@gmail.com)
Chairs: N Key (USA), F Peyvandi (Italy)
P. Monahan (USA) - Pathophysiology of factor IX inhibitors
J. Ingerslev (Denmark) - Clinical aspects of inhibitors in hemophilia B
C. Barnes (Australia) - Immune tolerance therapy for patients with FIX inhibitors

Bayer Special Lecture
M. Maas Enriquez (Germany) Recombinant factor VIII: a new development forextension of efficacy

Baxter
Chair: PM Mannucci (Italy)
P. Turecek (Austria) - Preclinical development of a plasma/albumin-free recombinant VWF (rVWF-PFM)
T. Suiter (Austria) - rVWF-PFM: the clinical development challenge
B. Reipert (Austria) - Questions on the putative role of VWF and modulation of FVIII immune response to hemophilia A

Scientific Session 2
Chairs: M van den Berg (The Netherlands), S Lacroix-Desmazes (France)
S Lacroix-Desmazes (France) A role for exposed mannosylations in presentation of human therapeutic self-proteins to CD4+ T lymphocytes
B Reipert (Austria) A new murine model for hemophilia A that expresses human MHC-class II on the background of a knockout of the murine MHC-class II
M van den Berg (The Netherlands) Clinical determinants for inhibitor development in severe hemophilia A: the introduction of a risk model
C Hay (UK) Inhibitors in previously treated patients: epidemiology, risk-factors and implications for clinical trials
M Makris (UK) Current issues in liver disease in hemophilia

Monday, 19 May 2008

Scientific Session 3
Chairs: P Lenting (The Netherlands), ZM Ruggeri (USA)
C Denis (France) A mouse model to study von Willebrand factor structure-functions relationships in vivo
P Lenting (The Netherlands) Clearance of the FVIII-VWF complex
D Lillicrap (Canada) The influence of VWF sequence variation on clearance and ADAMTS13 cleavage
J Voorberg (The Netherland) Dynamics and exocytosis of Weibel-Palade bodies in endothelial cells

Chairs: H Deckmyn (Belgium), I Peake (UK)
H Deckmyn (Belgium) Rational design of small molecule inhibitors of the collagen-VWF-GPIb interaction
ZM Ruggeri (USA) Physiologic modulation of VWF-GP Ib interactions: new functions of old molecules
V Flood (USA) VWF polymorphisms can sabotage the VWF:Rco assay of VWF function

Satellite Symposia
Grifols
Chairs: L.M. Aledort (USA), A. Gringeri (Italy)
S. Kaveri (France) - VWF and the immune response to FVIII. Antigen-presenting cells and uptake of FVIII/VWF
W. Kreuz (Germany) - VWF/FVIII and inhibitors in Hemophilia A patients
M. Heisel-Kurth (USA) - VWF/FVIII concentrates in immune tolerance induction

Novo Nordisk
Chairs: E. Santagostino (Italy), M. Morfini (Italy)
S. Seremetis (USA) - Future hemostasis (analogues of FVIIa, sc rFVIIa and rFVIII)
B. Konkle (USA) - Arthropathy: new treatment concepts. Clinical results of 151 phase II core trial

Scientific Session 4
Chair: D Ginsburg (USA), DA Lane (UK)
D Ginsburg (USA) Identifying modifier genes for von Willebrand disease and other disorders of hemostasis
R Schneppenheim (Germany) Molecular mechanisms of VWD beyond the subtype level
F Rodeghiero (Italy) Diagnosis and management of VWD in the light of results of international studies
K Vanhoorelbeke (Belgium) Towards gene therapy for von Willebrand disease

Tuesday, 20 May 2008

Scientific Session 5
Chairs: F Bernardi (Italy), B Laemmle (Switzerland)
A Gringeri (Italy) The ESPRIT study: a randomized trial of prohylaxis in Italian children with severe hemophilia
E Santagostino (Italy) Modifiers of hemophilia phenotype
AB Federici (Italy) Role of VWF in megakaryocyte formation
M Pinotti (Italy) Rescue of coagulation factor VII expression impaired by nonsense and splicing mutations
R De Cristofaro (Italy) Effects of VWF on the interaction with ADAMTS13 implication for prothrombotic effects of oxidative stress.
F Peyvandi (Italy) Issues with ADAMTS13 assays
M Galbusera (Italy) ADAMTS13 and complement interplay in the pathogenesis of thrombotic microangiopathis

Poster Discussion

Scientific Session 6
Chairs: P de Groot (The Netherlands), L Zheng (USA)
J-F Dong (USA) Redox regulation of VWF adhesion activity
DA Lane (UK) The interaction of ADAMTS13 with von Willebrand factor
L Zheng (USA) Cofactor-mediated regulation of ADAMTS13 function
P de Groot (The Netherlands) The active conformation of von Willebrand factor in thrombotic thrombocytopenic purpura (TTP)

Chairs: HM Tsai (USA), F Scheiflinger (Austria)
H-M Tsai (The Netherlands) ADAMTS13: genotype and phenotype
F Scheiflinger (Austria) Characterization of the immune response to ADAMTS13 in TTP patients
J Kremer-Hovinga (Switzerland) New insights into the autoimmune pathogenesis of acquired TTP
J Caprioli (Italy) Genetics of non-Stx-HUS